Skip to main content

Table 2 Baseline clinical characteristics of patients stratified by the optimal cutoff point of TyG index

From: Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China

  Total population (n = 798) Lower TyG index (< 9.18; n = 429) Higher TyG index (≥ 9.18; n = 369) P value
Age, years 60.9 ± 8.3 62.1 ± 7.9 59.5 ± 8.5 < 0.001
Sex, male, n (%) 545 (68.3) 303 (70.6) 242 (65.6) 0.127
BMI, kg/m2 26.7 ± 3.2 26.3 ± 3.2 27.1 ± 3.2 < 0.001
Heart rate, bpm 71.7 ± 10.2 70.9 ± 9.6 72.5 ± 10.8 0.028
SBP, mmHg 131.8 ± 17.1 131.3 ± 16.8 132.2 ± 17.5 0.443
DBP, mmHg 76.8 ± 10.1 76.2 ± 10.1 77.6 ± 10.1 0.051
Smoking, n (%) 417 (52.3) 227 (52.9) 190 (51.5) 0.688
Drinking, n (%) 184 (23.1) 106 (24.7) 78 (21.1) 0.233
Family history of CAD, n (%) 93 (11.7) 44 (10.3) 49 (13.3) 0.185
Duration of diabetes, years 8.2 ± 4.3 8.3 ± 4.3 8.2 ± 4.2 0.681
Medical history, n (%)
 Hypertension 573 (71.8) 303 (70.6) 270 (73.2) 0.426
 Dyslipidemia 710 (89.0) 347 (80.9) 363 (98.4) < 0.001
 Prior MI 175 (21.9) 90 (21.0) 85 (23.0) 0.484
 Prior PCI 151 (18.9) 82 (19.1) 69 (18.7) 0.881
 Prior stroke 109 (13.7) 60 (14.0) 49 (13.3) 0.772
 Prior PVD 125 (15.7) 72 (16.8) 53 (14.4) 0.348
Laboratory results
 TGs, mg/dL 138.2 (97.2, 198.5) 99.2 (78.4, 127.1) 204.7 (164.4, 276.0) < 0.001
 TC, mg/dL 157.2 ± 39.7 145.9 ± 35.0 170.4 ± 40.8 < 0.001
 LDL-C, mg/dL 94.2 ± 33.1 88.2 ± 30.5 101.1 ± 34.6 < 0.001
 HDL-C, mg/dL 36.9 ± 8.7 38.7 ± 9.3 34.8 ± 7.3 < 0.001
 hs-CRP, mg/L 1.6 (0.7, 4.1) 1.3 (0.6, 4.2) 1.9 (0.9, 3.9) 0.009
 Creatinine, mg/dL 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.655
 eGFR, mL/(min * 1.73 m2) 96.5 ± 21.6 96.6 ± 21.3 96.5 ± 22.0 0.992
 Uric acid, μmol/L 328.0 ± 75.6 322.2 ± 74.9 334.8 ± 75.9 0.019
 FBG, mg/dL 127.7 (109.6, 157.0) 115.4 (102.3, 133.1) 149.9 (125.3, 177.8) < 0.001
 HbA1c, % 7.5 ± 1.3 7.1 ± 1.2 7.8 ± 1.3 < 0.001
 TyG index 9.1 ± 0.6 8.6 ± 0.4 9.7 ± 0.4 < 0.001
 LVEF, % 64.0 ± 6.6 64.0 ± 6.8 64.0 ± 6.4 0.986
Initial diagnosis, n (%) 0.022
 UA 650 (81.5) 362 (84.4) 288 (78.0)  
 NSTEMI 148 (18.5) 67 (15.6) 81 (22.0)  
Pre-admission medication, n (%)
 ACEI 79 (9.9) 44 (10.3) 35 (9.5) 0.716
 ARB 128 (16.0) 66 (15.4) 62 (16.8) 0.586
 DAPT 253 (31.7) 136 (31.7) 117 (31.7) 0.999
 Aspirin 427 (53.5) 226 (52.7) 201 (54.5) 0.613
 Clopidogrel 264 (33.1) 141 (32.9) 123 (33.3) 0.889
 β-blocker 166 (20.8) 92 (21.4) 74 (20.1) 0.629
 Statins 233 (29.2) 127 (29.6) 106 (28.7) 0.786
 Proton pump inhibitor 8 (1.0) 4 (0.9) 4 (1.1) 0.830
 Oral hypoglycemic agents 413 (51.8) 220 (51.3) 193 (52.3) 0.773
 Metformin 170 (21.3) 101 (23.5) 69 (18.7) 0.096
 Alpha-glucosidase inhibitor 185 (23.2) 100 (23.3) 85 (23.0) 0.927
 Sulfonylurea 126 (15.8) 67 (15.6) 59 (16.0) 0.886
 Dipeptidyl peptidase 4 inhibitor 15 (1.9) 7 (1.6) 8 (2.2) 0.578
 Insulin 225 (28.2) 109 (25.4) 116 (31.4) 0.059
Post-discharge medication, n (%)
 ACEI 234 (29.3) 114 (26.6) 120 (32.5) 0.066
 ARB 384 (48.1) 204 (47.6) 180 (48.8) 0.729
 DAPT 796 (99.7) 429 (100.0) 367 (99.5) 0.214
 DAPT interruption in 12 months 12 (1.5) 7 (1.6) 5 (1.4) 0.749
 Aspirin 797 (99.9) 429 (100.0) 368 (99.7) 0.462
 Clopidogrel 797 (99.9) 429 (100.0) 368 (99.7) 0.462
 β-blocker 744 (93.2) 400 (93.2) 344 (93.2) 0.993
 Statins 787 (98.6) 423 (98.6) 364 (98.6) 0.958
 Statins interruption in 12 months 31 (3.9) 14 (3.3) 17 (4.6) 0.327
 Proton pump inhibitor 790 (99.0) 426 (99.3) 364 (98.6) 0.568
 Oral hypoglycemic agents 409 (51.3) 217 (50.6) 192 (52.0) 0.683
 Metformin 167 (20.9) 98 (22.8) 69 (18.7) 0.151
 Alpha-glucosidase inhibitor 181 (22.7) 97 (22.6) 84 (22.8) 0.959
 Sulfonylurea 123 (15.4) 64 (14.9) 59 (16.0) 0.676
 Dipeptidyl peptidase 4 inhibitor 15 (1.9) 7 (1.6) 8 (2.2) 0.578
 Insulin 217 (27.2) 104 (24.2) 113 (30.6) 0.043
Angiographic data
 LM disease, n (%) 44 (5.5) 19 (4.4) 25 (6.8) 0.148
 One-vessel disease, n (%) 167 (20.9) 92 (21.4) 75 (20.3) 0.698
 Two-vessel disease, n (%) 287 (36.0) 163 (38.0) 124 (33.6) 0.197
 Three-vessel disease, n (%) 344 (43.1) 174 (40.6) 170 (46.1) 0.117
 Chronic total occlusion, n (%) 117 (14.7) 55 (12.8) 62 (16.8) 0.113
 Diffuse lesion, n (%) 237 (29.7) 123 (28.7) 114 (30.9) 0.493
 Bifurcation lesion, n (%) 186 (23.3) 93 (21.7) 93 (25.2) 0.240
 In-stent restenosis, n (%) 58 (7.3) 28 (6.5) 30 (8.1) 0.384
 SYNTAX score 12.0 ± 5.5 11.6 ± 5.5 12.6 ± 5.6 0.010
Procedural results
 Target vessel territory, n (%)
  LM 25 (3.1) 14 (3.3) 11 (3.0) 0.819
  LAD 513 (64.3) 274 (63.9) 239 (64.8) 0.791
  LCX 335 (42.0) 185 (43.1) 150 (40.7) 0.480
  RCA 398 (49.9) 211 (49.2) 187 (50.7) 0.674
 DES implantation, n (%) 785 (98.4) 425 (99.1) 360 (97.6) 0.163
 DCB use, n (%) 15 (1.9) 5 (1.2) 10 (2.7) 0.109
 Complete revascularization, n (%) 414 (51.9) 229 (53.4) 185 (50.1) 0.360
 Number of stents 2.1 ± 1.3 2.1 ± 1.3 2.1 ± 1.3 0.700
  1. The groups were stratified by the optimal cutoff point of TyG index determined by ROC curve analysis
  2. Italic values indicate statistically significant associations
  3. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CAD coronary artery disease, MI myocardial infarction, PCIpercutaneous coronary intervention, PVD peripheral vascular disease, TGs triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein, eGFR estimated glomerular filtration rate, FBG fasting blood glucose, HbA1c glycosylated hemoglobin A1c, TyG triglyceride glucose, LVEF left ventricular ejection fraction, UA unstable angina, NSTEMI non-ST-segment elevation myocardial infarction, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, DAPT dual antiplatelet therapy, LM left main artery, SYNTAX synergy between PCI with taxus and cardiac surgery, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, DES drug-eluting stent, DCB drug-coated balloon